GenFleet Therapeutics (Shanghai) Inc. (SEHK: 2595)
Health Care · Biotechnology · CN
HK$28.60
-10.46% today · -16.6% 1Y
GenFleet Therapeutics (Shanghai) Inc. (SEHK: 2595) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.35B and employs 102 people.
Over the last twelve months the share price has lost 16.6%, trading between 19.60 and 52.90.
Tweenvest scores GenFleet Therapeutics (Shanghai) Inc. across four factors: quality 56/100, value 34/100. Its strongest factor is quality.
2595 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.35B
- Revenue (TTM)
- $12.37M
- P/E
- —
- EPS
- -3.74
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$52.90
- 52-week low
- HK$19.60
- Avg volume (3M)
- —
- Shares outstanding
- 370.37M
- Employees
- 102
- Next earnings
- —
About GenFleet Therapeutics (Shanghai) Inc.
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the treatment of advanced NSCLC; and GFH009, a highly selective cyclin-dependent kinase (CDK) 9 inhibitor in a Phase II trial for the treatment of AML. It is also developing GFH276, a pan-RAS inhibitor in a Phase I trial for the treatment of solid tumors; GFS202A, a bispecific antibody in a Phase I trial for the treatment of cachexia; GFH312, a receptor-interacting serine/threonine-protein kinase (RIPK) 1 inhibitor in a Phase I clinical trial for the treatment of PAD with IC and PBC; GFS784, a pan-RAS antibody drug conjugate (ADC) candidate with an IND application for the treatment of solid tumors; and GFH946, an oral PROTAC product candidate with an IND application for the treatment of type 2 inflammation. In addition, the company offers technical services. It has collaboration agreements with Merck Healthcare KGaA for trials of combinational regimens, including cetuximab; Verastem, Inc. to develop and commercialize GFH375; and SELLAS Life Sciences Group, Inc. to develop, manufacture, and commercialize GFH009. GenFleet Therapeutics (Shanghai) Inc. was incorporated in 2017 and is headquartered in Shanghai, China.
- ISIN
- CNE1000074L2
- Founded
- 2017
- Listed since
- Sep 19, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AnaptysBio, Inc.NasdaqGS: ANAB | $1.37B | $46.08 | +0.28% |
| Tyra Biosciences, Inc.NasdaqGS: TYRA | $1.37B | $19.60 | -1.71% |
| Chongqing Genrix Biopharmaceutical Co., Ltd.SHSE: 688443 | $1.37B | CN¥24.95 | -1.38% |
| Idorsia LtdSWX: IDIA | $1.36B | CHF4.20 | -5.83% |
| Pharma Mar, S.A.BME: PHM | $1.35B | €68.30 | -1.66% |
| BeBetter Med Inc.SHSE: 688759 | $1.35B | CN¥20.05 | -7.56% |
| GNI Group Ltd.TSE: 2160 | $1.33B | ¥3,200.00 | -3.18% |
| Biotest GmbH & Co. KGaAHMSE: BIO0 | $1.33B | €30.00 | -9.64% |
Figures last refreshed Oct 11, 2026.